Research has led to progress against many types of cancer:
- Better Treatments
- a Lower Chance of Death from the Disease
- and Improved Quality of Life.
Through research, knowledge about cancer keeps increasing. Scientists are learning more about what causes cancer and are finding new ways to prevent, detect, diagnose, and treat this disease.
Highlands Oncology Group, PA has been participating in clinical trials for over 15 years. The research department started with a small staff of one who performed all duties. Today, our current staff includes a Research Director, 2 Phase I Coordinators, 5 Phase II/III/IV Coordinators, 2 Medical Assistants, 3 Data Managers, and 3 Regulatory Specialist. Typically there are 25-35 open and accruing trials with 3-5 more pending. The trials cover a variety of cancer diagnoses. Highlands Oncology Group, PA has the privilege of being the only community Phase I Oncology clinical site in the state of Arkansas.
Clinical trials are a treatment option for many people living with cancer. The next few pages may help to explain clinical trials and give you something to think about when deciding whether or not to participate.
|S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors||OTHER||06/24/2019||View Here|
|Breast; Triple Negative - C3441020||BREAST||06/24/2019||View Here|
|CLAG525B2101 - Breast - Advanced TNBC||BREAST||06/24/2019||View Here|
|S1207 - Hormone receptor positive /HER-2 negative Breast Cancer||BREAST||06/24/2019||View Here|
|S1418 - TNBC with Residual Invasive Cancer||BREAST||06/24/2019||View Here|
|A011106 - Breast Estrogen + HER –||BREAST||06/24/2019||View Here|
|D8730C00001 (REFMAL 435) - COLORECTAL- metastatic||COLORECTAL||06/24/2019||View Here|
|Indolent B-Cell non-Hodgkin’s Lymphoma (iNHL) - Chronos-3||LYMPHOMA - Non Hodgkins (NHL)||06/24/2019||View Here|
|CA209592 - NSCLC-Stage IV||LUNG - Non Small Cell Cancer (NSCLC)||06/24/2019||View Here|
|B9991033 - NSCLC- metastatic, RAS +||LUNG - Non Small Cell Cancer (NSCLC)||06/24/2019||View Here|
|CINC280D2201 - NSCLC-Locally Advanced/Metastatic-EGFR/ALK Negative||LUNG - Non Small Cell Cancer (NSCLC)||06/24/2019||View Here|
|B9991030 - Ovarian Cancer- Untreated Stage III-IV (Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal)||OVARIAN||06/24/2019||View Here|
|WO40181 Breast Cancer, ER+, HER2-Locally advanced or Metastatic||BREAST||06/24/2019||View Here|
|CPDR001C2101 NSCLC- stage IIIB or IV||LUNG - Non Small Cell Cancer (NSCLC)||06/24/2019||View Here|
|B9991025 ADV/MET SOLID TUMOR||OTHER||06/24/2019||View Here|
|I3Y-MC-JPBH Breast –Metastatic-Phase 1||BREAST||06/24/2019||View Here|
|M16-298 (MERU) Extensive Stage SCLC - Maintenance||LUNG - Small Cell Cancer (SCLC)||06/24/2019||View Here|
|CA 209914 “CheckMate 914” Renal Cell Carcinoma – Previously Untreated, Localized Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse.||RENAL CELL||06/24/2019||View Here|
|I3Y-MC-JPCE NSCLC KRAS and PDL1 positive, stage IV||BREAST||06/24/2019||View Here|
|VX15/2503-04 NSCLC – Stage IV||LUNG - Non Small Cell Cancer (NSCLC)||06/24/2019||View Here|
|UTX-TGR-204 Lymphocytic Leukemia- Chronic||LEUKEMIA - Chronic Lymphocytic||06/24/2019||View Here|
|BBI-DSP7888-201G Recurrent or Progressive Glioblastoma||GLIOBLASTOMA||06/24/2019||View Here|
|ML28897-PRO02 Pathway Activated Solid Tumors||OTHER||06/24/2019||View Here|